Dataset Information

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

ABSTRACT: Phase I trial to study genetic testing and the effectiveness of irinotecan in treating patients who have solid tumors and lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person’s genetic makeup

DISEASE(S): Extranodal Marginal Zone B-cell Lymphoma Of Mucosa-associated Lymphoid Tissue,Lymphoma, Large B-cell, Diffuse,Stage Iv Adult T-cell Leukemia/lymphoma,Stage Iv Adult Diffuse Large Cell Lymphoma,Lymphoma, Large-cell, Immunoblastic,Small Intestine Lymphoma,Stage Iv Adult Diffuse Mixed Cell Lymphoma,Stage Iv Adult Immunoblastic Large Cell Lymphoma,Recurrent Grade 1 Follicular Lymphoma,Sezary Syndrome,Splenic Marginal Zone Lymphoma,Mycosis Fungoides,Lymphoma, Mantle-cell,Stage Iv Adult Lymphoblastic Lymphoma,Aids-related Peripheral/systemic Lymphoma,Stage Iii Adult Burkitt Lymphoma,Leukemia-lymphoma, Adult T-cell,Stage Iii Adult Diffuse Small Cleaved Cell Lymphoma,Recurrent Adult Immunoblastic Large Cell Lymphoma,Stage Iv Grade 1 Follicular Lymphoma,Recurrent Adult Burkitt Lymphoma,Stage Iv Mantle Cell Lymphoma,Primary Central Nervous System Non-hodgkin Lymphoma,Leukemia, T-cell,Plasmablastic Lymphoma,Stage Iv Mycosis Fungoides/sezary Syndrome,Aids-related Primary Cns Lymphoma,Lymphoma, B-cell, Marginal Zone,Burkitt Lymphoma,Stage Iii Mycosis Fungoides/sezary Syndrome,Recurrent Adult Diffuse Small Cleaved Cell Lymphoma,Stage Iii Grade 1 Follicular Lymphoma,Stage Iii Adult Immunoblastic Large Cell Lymphoma,Nodal Marginal Zone B-cell Lymphoma,Stage Iii Marginal Zone Lymphoma,Stage Iii Adult Diffuse Mixed Cell Lymphoma,Recurrent Small Lymphocytic Lymphoma,Lymphoma, T-cell, Cutaneous,Stage Iv Adult Burkitt Lymphoma,Recurrent Marginal Zone Lymphoma,Stage Iii Adult T-cell Leukemia/lymphoma,Lymphoma, Follicular,Stage Iii Adult Diffuse Large Cell Lymphoma,Leukemia, Lymphocytic, Chronic, B-cell,Intraocular Lymphoma,Stage Iii Cutaneous T-cell Non-hodgkin Lymphoma,Recurrent Mantle Cell Lymphoma,Recurrent Grade 3 Follicular Lymphoma,Stage Iii Adult Hodgkin Lymphoma,Leukemia,Hodgkin Disease,Recurrent Adult Hodgkin Lymphoma,Mycoses,Stage Iii Grade 2 Follicular Lymphoma,Angioimmunoblastic T-cell Lymphoma,Recurrent Adult Lymphoblastic Lymphoma,Stage Iv Marginal Zone Lymphoma,Unspecified Adult Solid Tumor, Protocol Specific,Lymphoma, Large-cell, Anaplastic,Stage Iv Adult Hodgkin Lymphoma,Stage Iii Mantle Cell Lymphoma,Lymphoma, T-cell,Stage Iii Grade 3 Follicular Lymphoma,Stage Iv Grade 3 Follicular Lymphoma,Stage Iv Adult Diffuse Small Cleaved Cell Lymphoma,Immunoblastic Lymphadenopathy,Precursor Cell Lymphoblastic Leukemia-lymphoma,Recurrent Cutaneous T-cell Non-hodgkin Lymphoma,Stage Iv Small Lymphocytic Lymphoma,Lymphoma,Recurrent Mycosis Fungoides/sezary Syndrome,Anaplastic Large Cell Lymphoma,Recurrent Adult Diffuse Mixed Cell Lymphoma,Stage Iii Small Lymphocytic Lymphoma,Recurrent Grade 2 Follicular Lymphoma,Stage Iv Cutaneous T-cell Non-hodgkin Lymphoma,Stage Iv Grade 2 Follicular Lymphoma,Recurrent Adult T-cell Leukemia/lymphoma,Lymphoma, Non-hodgkin,Stage Iii Adult Lymphoblastic Lymphoma,Recurrent Adult Diffuse Large Cell Lymphoma,Lymphoma, B-cell

PROVIDER: 2003426 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:This study, conducted by NHGRI and the M.D. Anderson Cancer Center in Houston, Texas, will develop statistical approaches for modeling family social structure and apply these models to explore the role of family social structure in participation in genetic testing and counseling, disclosure of test results and adjustment to risk status. With recent genetic advances and the ability to test for hereditary illnesses, methods that provide an understanding of the family social structure and how that structure affects the dissemination of genetic risk information are increasingly important. The data for this study were collected by the M.D. Anderson Cancer Center as part of a study on family communication and family functioning with regard to genetic testing for hereditary nonpolyposis colon cancer (HNPCC). Relatives of people with HNPCC are more likely than the general population to get colon cancer and other types of cancer if they have inherited the gene alteration (mutation) that predisposes to the disease. This alteration can be passed on from a parent to some or all of his or her children. In the M.D. Anderson Cancer Center study, telephone interviews were conducted with 80 adult members of 16 extended families with a known gene alteration predisposing for HNPCC. These participants included people who had been diagnosed with an HNPCC syndrome cancer, their unaffected family members who were at risk of carrying a gene mutation for HNPCC, and their spouses. Participants were interviewed about their feelings, moods, coping style, and relationships with their spouse, relatives, and friends, about their willingness to have genetic testing, and about their feelings and beliefs about colon cancer, cancer screening and genetic testing and counseling. Some participants were asked about their family communication style and how the family coped with the idea of genetic testing and with the results, if testing was done. The information obtained from the current study may help facilitate family participation, communication and psychological adjustment regarding risk information about genetic diseases.

Project description:Background and study aims Patients who are diagnosed with womb, bowel, or ovarian cancer that fulfill NHS genetic testing criteria are recommended to have genetic testing to see if their cancer was related to an inherited gene alteration. Identifying carriers of alterations allows novel personalised cancer treatments, prevention of second cancers, and testing of family members for cancer screening and prevention. Genetic testing requires pre-test counselling to ensure patients are informed about the impact of having a genetic test and managing the result. This ‘genetic counselling’ has traditionally been provided by genetics services. However, it is now routinely being offered by cancer-treating teams in an approach called “mainstreaming”. Currently, the demand for genetic counselling and testing is swiftly increasing and capacity constraints requires the development of new scalable cost and resource-efficient implementation models. This study will assess if pre-test counselling and genetic testing can be done using a direct-to-patient model. Participants will receive genetic testing information on a smartphone app or website that they can access at home along with counselling support through a study telephone helpline. Those who agree to testing can consent via the app and perform testing at home with a saliva genetic testing kit delivered and returned by post. In the study this direct-to-patient approach is directly compared to the standard mainstreaming approach. Who can participate? Patients aged 18 years and over diagnosed with bowel, womb, or ovarian cancer who are eligible for NHS genetic testing What does the study involve? This study compares and evaluates the uptake of genetic testing using both approaches. The researchers also assess patient satisfaction, quality-of-life, and psychological outcomes following testing, using standardized or customized questionnaires over 1 year of follow-up. Clinician opinions will be elicited. Some patients will also be interviewed to assess attitudes, experiences, and impact on emotional wellbeing. An economic analysis will be undertaken to assess the cost-effectiveness of this approach for the NHS.

Dataset Information

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure